首页> 外文OA文献 >Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful stratification into rituximab or r-chop consolidation in an international, prospective, multicenter Phase II trial

【2h】

Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful stratification into rituximab or r-chop consolidation in an international, prospective, multicenter Phase II trial

机译：对利妥昔单抗诱导的反应是B细胞移植后淋巴增生性疾病的一种预测标志物，并允许一项国际，前瞻性，多中心的II期临床试验成功地将其分为利妥昔单抗或r-chop合并

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Trappe, Ralf U.; Dierickx, Daan; Zimmermann, Heiner; Morschhauser, Franck; Mollee, Peter; Zaucha, Jan M.; Dreyling, Martin H.; Duhrsen, Ulrich; Reinke, Petra; Verhoef, Gregor; Subklewe, Marion; Huttmann, Andreas; Tousseyn, Thomas; Salles, Gilles; Kliem, Volker; Hauser, Ingeborg A.; Tarella, Corrado; Neste, Eric Van Den; Gheysens, Olivier; Anagnostopoulos, Ioannis; Leblond, Veronique; Riess, Hanno; Choquet, Sylvain;
展开▼
作者单位

展开▼
年度 2017
总页数
原文格式 PDF
正文语种 eng
中图分类

相似文献

外文文献
中文文献
专利

1. Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial [J] . Trappe Ralf U., Dierickx Daan, Zimmermann Heiner, Journal of Clinical Oncology . 2017,第5期

机译：对Rituximab诱导的反应是B细胞移植后淋巴抑制性疾病中的预测标志物，并在国际，前瞻性期II试验中成功分层或Rituximab或R-Checon Consolidation
2. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): The prospective international multicentre phase 2 PTLD-1 trial [J] . TrappeR., OertelS., LeblondV., The lancet oncology . 2012,第2期

机译：成年B细胞移植后淋巴增生性疾病（PTLD）的先后应用利妥昔单抗和CHOP化疗的序贯治疗：前瞻性国际多中心2期PTLD-1试验
3. Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease | Haematologica [J] . Eva González-Barca, Eva Domingo-Domenech, Francisco Javier Capote, Haematologica . 2007,第11期

机译：利妥昔单抗延长治疗B细胞移植后淋巴增生性疾病的前瞻性II期试验血液学
4. Successful Treatment of a Patient With Epstein-Barr Virus–Positive B-Cell Lymphoproliferative Disorder Resembling Post-Transplant Lymphoproliferative Disorder Using Single-Agent Rituximab [O] . Norman I. Maldonado, Fernando Cabanillas, Elaine S. Jaffe, -1

机译：成功的治疗爱泼斯坦-巴尔病毒阳性的B细胞淋巴组织增生性疾病类似于使用单剂利妥昔单抗的移植后淋巴组织增生性疾病
5. Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial [O] . Trappe, Ralf U, Dierickx, Daan, Zimmermann, Heiner, 2016

机译：对利妥昔单抗诱导的反应是B细胞移植后淋巴组织增生性疾病的一种预测标记，并且可以在国际的，预期的，多中心的II期临床试验中成功分为利妥昔单抗或R-CHOP合并

Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful stratification into rituximab or r-chop consolidation in an international, prospective, multicenter Phase II trial

著录项

相似文献

相关主题

期刊订阅